Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
SymbioVaccin
Herborn, Hesse, Germanysymbiovaccin.de ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SymbioVaccin was a German biotechnology company specializing in the development and production of autogenous vaccines (autovaccines) and diagnostics. Based in Herborn, the company focused on personalized immunotherapy for chronic recurrent bacterial infections by using patient-specific pathogens to stimulate the immune system. Their product range included AutoColi Vaccine and infection-related autovaccines for various indications such as respiratory infections, acne, and allergic diseases. In 2023, SymbioVaccin was merged into its sister company, SymbioPharm GmbH, following the acquisition of the Symbio Group by Klinge Pharma.
- Therapeutic areas
- Infectious DiseasesWomen's HealthDermatologyImmunology
- Modalities
- VaccineBiologic
- Industry
- Biotech
02
Partnerships
Institut für Mikroökologie
Beyond the preview
Go deeper on SymbioVaccin.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SymbioVaccin.